Markets:

Overview

News

Currencies

International

Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

46.55 +0.48 (+1.03%)

Streaming Delayed Price Updated: 1:06 PM EDT, May 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

BioMedNewsBreaks — SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Advances Next-Generation GLP-1 Candidate as Obesity Drug Market Expands Rapidly

Today 10:11 EDT

Via Investor Brand Network

The Next Generation of the GLP-1 Revolution Is Already Underway

Today 10:05 EDT

Via Investor Brand Network

Is This News From Novo Nordisk a Warning for Eli Lilly Shareholders? ↗

May 09, 2026

The weight loss drug market is on track to reach almost $100 billion.

Via The Motley Fool

The Next Generation of the GLP-1 Revolution Is Already Underway

Today 8:30 EDT

From BioMedWire

Via GlobeNewswire

Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus ↗

May 08, 2026

As Hims & Hers pivots to branded GLP-1s via a Novo Nordisk deal, all eyes are on the company’s May 11 earnings as investors look for sustained subscriber growth.

Via MarketBeat

Forget Eli Lilly: These 2 Stocks Have More Upside ↗

May 07, 2026

Eli Lilly has a lofty valuation thanks to its strong GLP-1 growth, but don't count out these two competitors.

Via The Motley Fool

What the FDA's Latest Proposal Means for Lilly, Novo, and Hims ↗

May 07, 2026

The FDA's latest proposal would be a win for Eli Lilly and Novo Nordisk, while Hims & Hers Health would also garner indirect benefits.

Via MarketBeat

My Top Obesity Stock to Buy and Hold ↗

May 07, 2026

Most weight-loss stocks are built on future expectations. Eli Lilly is built on current earnings and expanding demand.

Via The Motley Fool

Record Highs, Punished Results, and One Very Consequential Apple Rumor ↗

May 06, 2026

Via Chartmill

3 Absurdly Cheap Growth Stocks to Buy in May 2026 ↗

May 04, 2026

These stocks have been struggling over the past year, but their growth days are far from over.

Via The Motley Fool

Here's Exactly Why Wall Street Thinks Viking Therapeutics Stock Could Soar 207% Over the Next 12 Months ↗

May 04, 2026

The Street is bullish on this biotech's prospects, but is the sentiment justified?

Via The Motley Fool

Eli Lilly Just Announced Fantastic News for Shareholders ↗

May 04, 2026

Lilly's weight loss drugs have been delivering blockbuster revenue.

Via The Motley Fool

Topics Earnings

Here's Why Shares in Agios Pharmaceuticals Soared This Week (And What to Expect Next in 2026) ↗

May 02, 2026

The company faces competitive pressure from Novo Nordisk, but it's growing sales from its existing approved drugs and has an exciting drug in its pipeline.

Via The Motley Fool

Lilly's Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It Permanent ↗

May 01, 2026

Via MarketBeat

Viking Therapeutics Faces Timeline Risk—But Upside Could Be Huge ↗

May 01, 2026

Via MarketBeat

What's the Next Big Thing After GLP-1 Drugs? CRISPR Therapeutics May Have the Answer. ↗

April 30, 2026

The biotech's candidate may treat a great number of illnesses that have one thing in common.

Via The Motley Fool

Is Eli Lilly Stock Undervalued at $870? 1 Top Wall Street Analyst Thinks So ↗

April 28, 2026

And he may be right.

Via The Motley Fool

Amazon Takes a Bite Out of Hims: What Its GLP-1 Entrance Means ↗

April 28, 2026

Via MarketBeat

Is This Deal a Game Changer for Novo Nordisk? ↗

April 27, 2026

The drugmaker is getting on the AI train in ways that could move the needle down the road.

Via The Motley Fool

Topics Artificial Intelligence

Forget Weight Loss Drugs: Here's An Even Better Reason to Invest in Eli Lilly ↗

April 27, 2026

Eli Lilly has more to offer than some investors realize.

Via The Motley Fool

This Obesity Stock Could More Than Double Over the Next 12 Months, According to Wall Street ↗

April 26, 2026

Most investors currently see the glass on this stock as being half-empty. Analysts, however, still view the glass as at least half-full.

Via The Motley Fool

Is This Tech Giant the Next Potential Winner in the GLP-1 Weight Loss Boom? ↗

April 25, 2026

The weight loss drug market may reach almost $100 billion in a few years.

Via The Motley Fool

Why Eli Lilly Stock Flopped on Friday ↗

April 24, 2026

High hopes for a freshly approved drug might not be realized, if early data is any indication.

Via The Motley Fool

Here's Why Agios Pharmaceuticals Stock Slumped This Week (And What Investors Have to Look Forward to in 2026) ↗

April 24, 2026

A rival company's trial results had a negative impact on Agios' stock this week.

Via The Motley Fool

Is Novo Nordisk's 72% Crash a Generational Buying Opportunity or a Value Trap? ↗

April 23, 2026

Novo Nordisk stock has been stuck in a downward spiral for quite some time.

Via The Motley Fool

The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial

April 23, 2026

From stem cell therapies for frailty to α-Klotho protein programs and GLP-1 drug classes now labeled "longevity therapeutics," the science and the capital have finally met

From Equity Insider

Via GlobeNewswire

Forget Ozempic: This High‑Flying Device Maker Can Thrive No Matter Which Weight Loss Drug Wins ↗

April 23, 2026

Drugmakers won't be the only ones cashing in on the rising popularity of weight loss medicines.

Via The Motley Fool

Stock Market Today, April 21: Hims & Hers Health Drops as Amazon Unveils Competing Weight Loss Program ↗

April 21, 2026

Telehealth investors weigh Amazon’s new anti-obesity drug push against this platform’s recent rapid growth, today, April 21, 2026.

Via The Motley Fool

Topics Stocks

A Monthly Weight Loss Shot? Why Pfizer Could Topple Lilly's and Novo's GLP-1 Duopoly ↗

April 21, 2026

There might be room for two titans in the obesity business, but a third player might have a uniquely marketable option.

Via The Motley Fool

Here's Why Agios Pharmaceuticals Crashed 23% Today ↗

April 20, 2026

The market is concerned about the diminished market potential for Agios' mitapavit following today's newsflow.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.